Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands.
Int J Cardiovasc Imaging. 2012 Oct;28(7):1643-52. doi: 10.1007/s10554-011-9989-9. Epub 2011 Dec 18.
This study is aimed at assessing by intravascular ultrasound virtual histology (VH-IVUS) the effect of statins on coronary bifurcation atherosclerosis in non-culprit vessels. In this non-randomized study, in 48 patients, 51 bifurcation atherosclerotic sites in non-culprit vessels without significant angiographic stenosis, underwent baseline and 12 months follow-up VH-IVUS. Patients received treatment with either simvastatin (20 mg daily, n = 24) or rosuvastatin (10 mg daily, n = 24) for the same period. VH-IVUS analysis of bifurcation lesions included the 5-mm proximal, bifurcation only (side-branch point) and 5-mm distal subsegments. Overall plaque and external elastic membrane volume decreased after 1 year (115.7 ± 35.5 to 106.1 ± 29.3 mm³, P < 0.001; and 241.0 ± 57.0 to 232.4 ± 54.2 mm³, P = 0.005, respectively). Similarly, overall dense calcium volume significantly increased (7.1 ± 5.3 to 11.0 ± 8.5 mm³, P < 0.010), while fibrous and fibrofatty volumes significantly decreased (36.9 ± 19.2 to 24.1 ± 11.7 mm³, P < 0.001; and 5.1 ± 3.8 to 2.3 ± 2.0 mm³, P < 0.001, respectively), and necrotic core volume did not change significantly (17.0 ± 11.1 to 19.8 ± 13.5 mm³, P = 0.053). There were no significant differences in compositional analysis between the simvastatin and rosuvastatin treatment groups. However, within groups, necrotic core volume significantly increased in the simvastatin treatment group (19.7 ± 13.9 to 24.3 ± 16.1 mm³, P = 0.029) but not in the rosuvastatin treatment group. (14.3 ± 6.7 to 15.6 ± 8.7 mm³, P = 0.423). The independent clinical predictors for reduction of necrotic core volume by multiple stepwise logistic regression analysis were the percent change of HDL-cholesterol level (P = 0.041, odds ratio: 1.052, 95% confidence interval (CI): 1.002 to 1.104) and the percent change of hsCRP level (P = 0.021, odds ratio: 0.989, 95% CI: 0.980 to 0.998). After 1 year, overall dense calcium volume significantly increased whilst fibrous and fibrofatty volumes significantly decreased; no significant change in the content of necrotic core was observed. Although changes in the volumes of all plaque components were not significantly different between the simvastatin and rosuvastatin treatment groups, halting of necrotic core progression was apparent in the rosuvastatin group.
本研究旨在通过血管内超声虚拟组织学(VH-IVUS)评估他汀类药物对非罪犯血管分叉处粥样硬化的影响。在这项非随机研究中,48 例患者的 51 个非罪犯血管分叉处粥样硬化病变,无明显血管造影狭窄,进行了基线和 12 个月的随访 VH-IVUS。患者接受辛伐他汀(20mg 每日,n=24)或瑞舒伐他汀(10mg 每日,n=24)治疗 1 年。VH-IVUS 分析分叉病变包括近端 5mm、分叉处(侧支分支点)和远端 5mm 亚段。1 年后斑块总体积和外膜弹性膜体积均减少(115.7±35.5mm³降至 106.1±29.3mm³,P<0.001;241.0±57.0mm³降至 232.4±54.2mm³,P=0.005)。同样,总致密钙体积显著增加(7.1±5.3mm³增至 11.0±8.5mm³,P<0.010),而纤维和纤维脂肪体积显著减少(36.9±19.2mm³降至 24.1±11.7mm³,P<0.001;5.1±3.8mm³降至 2.3±2.0mm³,P<0.001),坏死核心体积无显著变化(17.0±11.1mm³增至 19.8±13.5mm³,P=0.053)。辛伐他汀和瑞舒伐他汀治疗组之间的成分分析无显著差异。然而,在各组内,辛伐他汀治疗组的坏死核心体积显著增加(19.7±13.9mm³增至 24.3±16.1mm³,P=0.029),而瑞舒伐他汀治疗组无显著变化(14.3±6.7mm³增至 15.6±8.7mm³,P=0.423)。多元逐步逻辑回归分析显示,坏死核心体积减少的独立临床预测因子为高密度脂蛋白胆固醇水平变化百分比(P=0.041,优势比:1.052,95%置信区间(CI):1.002 至 1.104)和高敏 C 反应蛋白水平变化百分比(P=0.021,优势比:0.989,95%CI:0.980 至 0.998)。1 年后,总致密钙体积显著增加,而纤维和纤维脂肪体积显著减少;未观察到坏死核心含量的显著变化。尽管辛伐他汀和瑞舒伐他汀治疗组之间所有斑块成分体积的变化无显著差异,但瑞舒伐他汀组的坏死核心进展停止。